Abbott Laboratories Director Kevin Conroy's Form 3 Filing Following Exact Sciences Acquisition

This Form 3 filing reports the initial statement of beneficial ownership by Kevin T. Conroy, a director of Abbott Laboratories, following Abbott's acquisition of Exact Sciences Corporation. The filing discloses that Conroy owns 131,451 common shares of Abbott Laboratories. The shares represent a restricted stock unit (RSU) award that fully accelerated and became payable upon Conroy's separation from service following the Exact Sciences change in control at the effective time of the merger on March 23, 2026. One quarter of the award was settled immediately at the effective time, with the remaining three quarters to be settled six months and one day after the effective time. The acquisition involved Exact Sciences shareholders receiving $105.00 per share in cash, and certain Exact Sciences RSU awards were assumed by Abbott with double-trigger vesting protections. The filing includes a power of attorney document authorizing specific individuals to file SEC documents on Conroy's behalf.